第十八屆國家新創獎得獎研究主題分享
精準免疫幹細胞療法：雙基因修飾臍帶間質幹細胞治療實體癌症
此雙基因表現間質幹細胞可同時遞送程序性死亡受體(PD-1)與HSV-1-TK基因。此雙基因修飾間質幹細胞搭配更昔洛韋(ganciclovir)的注射，可啟動旁觀者效應來達到毒殺癌細胞之效果，並透過間質幹細胞中表現PD-1之特性，使其與癌細胞上表現之PD-L1結合，防止癌細胞與效應型T細胞 (effector T cells) 受腫瘤免疫抑制機制所影響，以維持效應型T細胞之免疫攻擊性。經基因工程改造後可使臍帶間質幹細胞能夠更全方位的將癌細胞毒殺。

Immune precision medicine: Development of dual genetic engineering umbilical cord mesenchymal stem cells in immunotherapy for solid tumor
The innovation of this application is that we apply gene engineering UMSCs on cancer therapy. Our group used "non-viral transfer technology" to establish "dual gene" expression UMSCs, which composed with suicide gene herpes simplex virus thymidine kinase (HSV-TK) and programmed death receptor 1 (PD-1). Through the bystander effect and the distant systemic immune response which induced by the suicide gene HSV-TK combined with drug ganciclovir (GCV), the death signal of itself and their surrounding tumor cells and immunosuppression signal were be activated. The activation of cell death signal in UMSCs can also prohibit the undesirable effect of the retention within tissue. Moreover, through the interaction of programmed death receptor 1 and programmed death ligand 1 (PD-L1) on tumor, it acts as an immune checkpoint inhibitor to weaken the immunosuppressive microenvironment around the tumor. UMSCs may precisely deliver therapeutic genes to cancer cells, followed with the activation of therapeutic genes by combining GCV to achieve precision medicine.